SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-22-001222
Filing Date
2022-01-10
Accepted
2022-01-10 08:23:36
Documents
13
Period of Report
2022-01-10
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea153715-8k_protarathera.htm   iXBRL 8-K 33434
2 PRESS RELEASE DATED JANUARY 10, 2022, ISSUED BY THE REGISTRANT ea153715ex99-1_protarathera.htm EX-99.1 11574
  Complete submission text file 0001213900-22-001222.txt   223678

Data Files

Seq Description Document Type Size
3 XBRL LABEL FILE tara-20220110_lab.xml EX-101.LAB 34240
4 XBRL PRESENTATION FILE tara-20220110_pre.xml EX-101.PRE 22361
5 XBRL SCHEMA FILE tara-20220110.xsd EX-101.SCH 3028
7 EXTRACTED XBRL INSTANCE DOCUMENT ea153715-8k_protarathera_htm.xml XML 3611
Mailing Address 345 PARK AVENUE SOUTH 3RD FLOOR NEW YORK NY 10010
Business Address 345 PARK AVENUE SOUTH 3RD FLOOR NEW YORK NY 10010 646-844-0337
Protara Therapeutics, Inc. (Filer) CIK: 0001359931 (see all company filings)

IRS No.: 204580525 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36694 | Film No.: 22519815
SIC: 2836 Biological Products, (No Diagnostic Substances)